Skip to main content
. Author manuscript; available in PMC: 2024 Feb 5.
Published in final edited form as: Lancet Microbe. 2023 Nov 3;4(12):e972–e982. doi: 10.1016/S2666-5247(23)00172-6

Figure 2: Timeline of bedaquiline treatment and follow-up isolate sampling per patient.

Figure 2:

Each circle represents individual bedaquiline phenotypic drug susceptibility testing done. Three (8%) of 40 patients were phenotypically resistant at baseline and follow-up (classified as group 1), and all had clofazimine exposure (prior or concurrent with bedaquiline). 19 (48%) of 40 patients acquired bedaquiline resistance during treatment (group 2); all but three (16%) of 19 had clofazimine exposure and all with a known treatment outcome had an unfavourable outcome. 18 (45%) of 40 patients were susceptible at both timepoints (group 3).